New York-based biopharmaceutical company, Perseus Therapeutics, announced plans to develop a novel thymic stromal lymphopoietin (TSLP) antibody designed to treat asthma and prevent hair loss in patients undergoing cancer therapy.
TSLP is an epithelial, cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades. It has recently gained significant attention in the medical and pharmaceutical communities for treating a wide range of inflammatory and allergic conditions.
“Perseus Therapeutics is committed to advancing the science of TSLP antibodies to meet critical unmet medical needs,” said Joseph Hernandez, MSc, chairman and founder of Perseus Therapeutics. “Our work aims not only to improve the quality of life for cancer patients by preventing hair loss but also to provide effective treatments for various inflammatory conditions.”
Perseus Therapeutics joins several companies and research groups who are actively exploring TSLP antibodies, including:
- AstraZeneca and Amgen developed tezepelumab, the first-in-class, anti-TSLP monoclonal antibody approved for severe asthma treatment.
- Johnson & Johnson acquired Proteologix to access its bispecific antibody targeting TSLP and IL-13.
- Blackstone launched Uniquity to advance Merck's phase 2, high-potency TSLP antibody.
- Innovent Biologics is conducting a phase 1 study on IBI3002, a dual-function antibody targeting both IL-4Rα and TSLP.
- Sanofi and Regeneron are developing SAR443765, a novel biologic targeting both TSLP and IL-13 for asthma.
- Teva Pharmaceuticals and Biolojic Design have entered into an exclusive license agreement to develop bispecific antibodies targeting TSLP and IL-13.
- GSK recently acquired Aiolos Bio for $1 billion upfront to enhance its respiratory biologics portfolio with AIO-001, a phase 2, long-acting, anti-TSLP monoclonal antibody.
